Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Verastem, Inc. (VSTM : NSDQ)

• Company Description    Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $9.45 Daily Weekly Monthly 20 Day Moving Average: 2,388,480 shares Shares Outstanding: 61.54 (millions) Market Capitalization: $581.60 (millions) Beta: 0.89 52 Week High: $11.25 52 Week Low: $3.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.62% 6.65% 12 Week 40.21% 30.97% Year To Date 82.79% 57.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 KENDRICK STREET SUITE 500 - NEEDHAM,MA 02494 USA ph: 781-292-4200 fax: - dcalkins@verastem.com http://www.verastem.com

• General Corporate Information    Officers Daniel W. Paterson - President and Chief Executive Officer Matthew E. Ros - Chief Operating Officer Daniel Calkins - Chief Financial Officer Paul Bunn - Director Robert Gagnon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92337C203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 61.54 Most Recent Split Date: 6.00 (0.08:1) Beta: 0.89 Market Capitalization: $581.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 14.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -25.81% vs. Previous Quarter: 59.38% Sales Growth vs. Year Ago Period: -78.63% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -119.85 03/31/25 - -127.97 Current Ratio 09/30/25 - - 06/30/25 - 3.46 03/31/25 - 3.50 Quick Ratio 09/30/25 - - 06/30/25 - 3.44 03/31/25 - 3.50 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -7,785.21 03/31/25 - -1,486.92 Book Value 09/30/25 - - 06/30/25 - 0.66 03/31/25 - -0.63 Inventory Turnover 09/30/25 - - 06/30/25 - 1.53 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 2.06 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - 67.32 03/31/25 - -

Powered by Zacks Investment Research ©